Cargando…

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

Detalles Bibliográficos
Autores principales:	Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Best Abstracts - Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012126/ http://dx.doi.org/10.1097/01.HS9.0000829556.56345.01

Ejemplares similares

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS
por: Mateos, M, et al.
Publicado: (2022)

S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS
por: Bahlis, Nizar J, et al.
Publicado: (2023)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: van de Donk, N., et al.
Publicado: (2023)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
por: Offner, Fritz, et al.
Publicado: (2023)

PB2132: EXCALIBER-RRMM: A PHASE 3, TWO-STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Lonial, Sagar, et al.
Publicado: (2023)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
por: Tan, Carlyn, et al.
Publicado: (2023)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

B01 Virtual reality as a teaching method for resuscitation training in undergraduate first year medical students during COVID-19 pandemic: A randomised controlled trial
por: Moll-Khosrawi, Parisa, et al.
Publicado: (2022)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Popat, R, et al.
Publicado: (2022)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Martínez-López, J., et al.
Publicado: (2022)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Teclistamab: First Approval
por: Kang, Connie
Publicado: (2022)

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1
por: van de Donk, N. W. C. J, et al.
Publicado: (2022)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mateos, M. V., et al.
Publicado: (2022)

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON
por: Rosinol, L., et al.
Publicado: (2022)

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON
por: Delforge, M., et al.
Publicado: (2022)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
por: Frerichs, Kristine, et al.
Publicado: (2023)

A Practical Guide to Sliding and Surface Semilandmarks in Morphometric Analyses
por: Bardua, C, et al.
Publicado: (2019)

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
por: Searle, E., et al.
Publicado: (2023)

P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL-1
por: Rasche, Leo, et al.
Publicado: (2023)

The Natural Historian's Guide to the CT Galaxy: Step-by-Step Instructions for Preparing and Analyzing Computed Tomographic (CT) Data Using Cross-Platform, Open Access Software
por: Buser, T J, et al.
Publicado: (2020)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

Using self-monitoring technology for nutritional counseling and weight management
por: Carpenter, Chelsea A, et al.
Publicado: (2022)

A CURE for a Major Challenge in Phenomics: A Practical Guide to Implementing a Quantitative Specimen-Based Undergraduate Research Experience
por: Price, S A, et al.
Publicado: (2020)

Applying an affordances approach and a developmental lens to approach adolescent social media use
por: Moreno, Megan A, et al.
Publicado: (2019)

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Gay, F, et al.
Publicado: (2022)

Michigan Pharmacists Transforming Care and Quality: Developing a Statewide Collaborative of Physician Organizations and Pharmacists to Improve Quality of Care and Reduce Costs
por: Choe, Hae Mi, et al.
Publicado: (2018)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

A Guide to Inverse Kinematic Marker-Guided Rotoscoping Using IK Solvers
por: Wiseman, Ashleigh L A, et al.
Publicado: (2022)

Federated learning for preserving data privacy in collaborative healthcare research
por: Loftus, Tyler J, et al.
Publicado: (2022)

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS
por: Musto, P., et al.
Publicado: (2023)

Provider-to-provider synchronous telemedical consultations in ophthalmology: Advice for implementation
por: Stewart, Carly, et al.
Publicado: (2022)

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
por: Hofste op Bruinink, D., et al.
Publicado: (2023)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
por: Quach, H., et al.
Publicado: (2022)

Best Practices: Improving Patient Outcomes and Costs in an ACO Through Comprehensive Medication Therapy Management
por: Brummel, Amanda, et al.
Publicado: (2014)

Learner Verification: A Methodology to Create Suitable Education Materials
por: Chavarria, Enmanuel A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lm30r5skgvcl09378nseolmhvl